Background

Bundibugyo virus (BDBV) is a member of the Ebola virus species and causes severe hemorrhagic fever. It was first identified in Uganda in 2007 and subsequently caused an outbreak in the Democratic Republic of the Congo in 2012. However, due to the limited number of reported cases, the natural reservoir and the route of introduction into the human population remain unclear. Unlike Zaire Ebola virus, there are no licensed BDBV-specific vaccines or therapeutics.

The outbreak that began in eastern Democratic Republic of the Congo in May 2026 spread across the border into Uganda. On May 17, the World Health Organization (WHO) declared it a Public Health Emergency of International Concern. Epidemiological investigations alone cannot determine whether the virus in this outbreak originated from a previously circulating virus in humans or animals, or whether it represents a new spillover event from a wild animal reservoir. In conflict-affected areas with high patient mobility and limited contact tracing, reconstructing the initial infection and the direction of cross-border transmission is even more challenging.

Key Findings

A study published in Nature Medicine analyzed the genomes of 22 BDBV isolates obtained from patients in the Democratic Republic of the Congo and Uganda. By performing phylogenetic analysis, the researchers compared the genetic distances and common ancestry of these genomes with previously characterized BDBV genomes to trace the origin of the current outbreak.

The 22 genomes analyzed suggest that the current outbreak cannot be explained by long-term, undetected transmission from previous cases or by simple re-emergence of the 2007 and 2012 outbreaks. The researchers' interpretation supports the hypothesis of an independent zoonotic spillover event, meaning that the virus was newly introduced into humans from an animal reservoir. The Ugandan cases appear to be linked to the outbreak in the Democratic Republic of the Congo, rather than representing a separate animal introduction. This is consistent with the WHO's report of imported cases and subsequent limited secondary transmission among contacts and healthcare workers.

It is important to note that 'new spillover' does not necessarily mean the emergence of an entirely new virus species. It refers to the phylogenetic finding that the existing BDBV pathogen has re-entered the human transmission cycle from its natural reservoir. Furthermore, the analysis of these 22 genomes alone is not sufficient to definitively determine whether specific mutations have increased the virus's transmissibility or virulence.

Significance and Implications

These findings highlight the need to broaden the focus of outbreak control beyond contact tracing among patients. Surveillance of wildlife and their habitats in the vicinity of the outbreak, as well as investigation of human-animal interactions in mining and forest fringe areas, are crucial for reducing the risk of future spillover events. Sharing viral genomes early in an outbreak can facilitate the rapid identification of cross-border transmission and independent zoonotic spillover events.

However, the current analysis is based on a limited sample size of 22 genomes, which may not fully represent the spatiotemporal diversity of the outbreak. Furthermore, the natural reservoir has not been directly identified. If the samples were primarily collected from severe cases or from areas with good access to healthcare, the resulting phylogenetic tree may be biased and not fully reflect the actual transmission dynamics. Future studies should include a larger number of viral genomes from patients, wildlife samples, and contact tracing data collected from a wider range of locations and time points. In vitro and in vivo studies are also needed to determine the impact of observed mutations on viral infectivity and immune evasion.